Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Johnson and Johnson
McKinsey
Merck
Express Scripts

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SYNRIBO

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Synribo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed Cephalon Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed ChemGenex Pharmaceuticals Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed Teva Branded Pharmaceutical Products R&D, Inc. Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed Teva Branded Pharmaceutical Products, R&D Inc. Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Synribo

Condition Name

Condition Name for Synribo
Intervention Trials
Chronic Myeloid Leukemia 2
Leukemia 2
Recurrent Acute Biphenotypic Leukemia 1
Recurrent Acute Myeloid Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Synribo
Intervention Trials
Leukemia, Myeloid 5
Preleukemia 4
Myelodysplastic Syndromes 4
Leukemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Synribo

Trials by Country

Trials by Country for Synribo
Location Trials
United States 21
Germany 2
Italy 2
United Kingdom 2
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Synribo
Location Trials
Texas 5
Pennsylvania 2
New York 2
Maryland 2
Indiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Synribo

Clinical Trial Phase

Clinical Trial Phase for Synribo
Clinical Trial Phase Trials
Phase 2 4
Phase 1/Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Synribo
Clinical Trial Phase Trials
Completed 3
Terminated 2
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Synribo

Sponsor Name

Sponsor Name for Synribo
Sponsor Trials
Teva Pharmaceuticals USA 3
M.D. Anderson Cancer Center 3
Teva Branded Pharmaceutical Products R&D, Inc. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Synribo
Sponsor Trials
Industry 12
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Johnson and Johnson
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.